UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 56

Sortiert nach

Osteoporotic pubic rami fracture: a benign injury?

Revista de la Facultad de Ciencias Médicas de Córdoba, 2018-03, Vol.75 (1), p.12-18

2018

Link zum Volltext

Verfügbarkeit prüfen

Use of silver coating in tumoral prosthetic surgery: influence on infection rate

Revista de la Facultad de Ciencias Médicas de Córdoba, 2017-09, Vol.74 (3), p.239-242

2017

Link zum Volltext

Verfügbarkeit prüfen

Optimizing chair time in infusion centers using intravenous cetirizine premedication for the prevention of hypersensitivity infusion reactions

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.e13508-e13508

2021

Link zum Volltext

Verfügbarkeit prüfen

Carpal tunnel syndrome due to heterotopic ossification

Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association, 2003-07, Vol.8 (4), p.596-598

2003

Link zum Volltext

Verfügbarkeit prüfen

Final results from TACTI-002 Part C: A phase II study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients with metastatic 2nd line head and neck squamous cell carcinoma unselected for PD-L1

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.6029-6029

2023

Link zum Volltext

Verfügbarkeit prüfen

Is physician-patient language discordance a barrier for clinical trial enrollment in patients with cancer? A real-life study

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e18539-e18539

2023

Link zum Volltext

Verfügbarkeit prüfen

AIPAC-003: A randomized, double-blind, placebo-controlled phase 3 trial testing eftilagimod alpha (soluble LAG-3) in patients with HER2-neg/low metastatic breast cancer receiving paclitaxel, following an open-label dose optimization

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.TPS1120-TPS1120

2023

Link zum Volltext

Verfügbarkeit prüfen

RNA sequencing as a confirmatory assay and its impact on patient care in multiple cancer types

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e15058-e15058

2023

Link zum Volltext

Verfügbarkeit prüfen

TACTI-003: A randomized phase IIb study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab as first-line treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.TPS6099-TPS6099

2022

Link zum Volltext

Verfügbarkeit prüfen

Safety and clinical activity of target-preserving anti-CTLA-4 antibody ONC-392 as monotherapy in NSCLC patients who progressed on PD(L)1-targeted immunotherapy

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.9024-9024

2023

Link zum Volltext

Verfügbarkeit prüfen

Results from a phase II study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients with PD-L1 unselected metastatic non-small cell lung carcinoma

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.9046-9046

2021

Link zum Volltext

Verfügbarkeit prüfen

A phase II study (TACTI-002) in first-line metastatic non–small cell lung carcinoma investigating eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab: Updated results from a PD-L1 unselected population

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.9003-9003

2022

Link zum Volltext

Verfügbarkeit prüfen

MT-6402, an engineered toxin body (ETB) targeting PD-L1: Interim efficacy and safety data

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.2552-2552

2023

Link zum Volltext

Verfügbarkeit prüfen

Initial results from a phase II study (TACTI-002) in metastatic non-small cell lung or head and neck carcinoma patients receiving eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.3100-3100

2020

Link zum Volltext

Verfügbarkeit prüfen

Resultado tras el tratamientoquirúrgico de tumores de células gigantes

Revista de la Facultad de Ciencias Médicas de Córdoba, 2016-12, Vol.73 (4), p.258-262

2016

Link zum Volltext

Verfügbarkeit prüfen

Ph I/II study of oral selective AXL inhibitor bemcentinib (BGB324) in combination with erlotinib in patients with advanced EGFRm NSCLC: End of trial update

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.9110-9110

2021

Link zum Volltext

Verfügbarkeit prüfen

Operational metrics for the ELAINE II study combining a traditional approach with a just-in-time model

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.1504-1504

2022

Link zum Volltext

Verfügbarkeit prüfen

A multicenter, phase II study of soluble LAG-3 (Eftilagimod alpha) in combination with pembrolizumab (TACTI-002) in patients with advanced non-small cell lung cancer (NSCLC) or head and neck squamous cell carcinoma (HNSCC)

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.TPS2667-TPS2667

2019

Link zum Volltext

Verfügbarkeit prüfen

A phase II, open-label study of tomivosertib (eFT508) added on to continued checkpoint inhibitor therapy in patients (pts) with insufficient response to single-agent treatment

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.3112-3112

2020

Link zum Volltext

Verfügbarkeit prüfen

Leveraging machine learning technology to efficiently identify and match patients for precision oncology clinical trials

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.e13588-e13588

2021

Link zum Volltext

Verfügbarkeit prüfen

A phase 1b, open-label, single-arm study of cofetuzumab pelidotin (a PTK7-targeting antibody-drug conjugate) in patients with PTK7-expressing, recurrent non-small cell lung cancer (NSCLC)

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.TPS3142-TPS3142

2021

Link zum Volltext

Verfügbarkeit prüfen

Safety and efficacy of eflapegrastim in reducing severe neutropenia in patients treated with myelosuppressive chemotherapy in a phase 3 randomized controlled trial compared to pegfilgrastim (ADVANCE trial)

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.e12513-e12513

2018

Link zum Volltext

Verfügbarkeit prüfen

Uso de recubrimientos protésicos de plata en cirugía tumoral: influencia en la tasa de infección

Revista de la Facultad de Ciencias Médicas de Córdoba, 2017-09, Vol.74 (3), p.239

2017

Link zum Volltext

Verfügbarkeit prüfen

Genomic mutation profiling (GMP) and clinical outcome in patients (pts) treated with ribociclib (CDK4/6 inhibitor) in the Signature program

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.2528-2528

2016

Link zum Volltext

Verfügbarkeit prüfen

Operational Metrics for the ELAINE 2 Study Combining a Traditional Approach With a Just-in-TIME Model

JCO clinical cancer informatics, 2023-06, Vol.7, p.e2200164

2023

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 56

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(50)
Mit Volltextzugriff
(50)

Publikationsform

Artikel
(54)
Buchkapitel
(2)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(14)
Life Sciences & Biomedicine
(12)
Humans
(7)
Female
(6)
Plant Sciences
(5)
Biological And Medical Sciences
(4)
Plant Leaves - Physiology
(4)
Adult
(3)
Ecology
(3)
Environmental Sciences & Ecology
(3)
Male
(3)
Middle Aged
(3)
Treatment Outcome
(3)
Carbon Dioxide - Metabolism
(2)
Engineering
(2)
Engineering, Electrical & Electronic
(2)
Follow-Up Studies
(2)
Fundamental And Applied Biological Sciences. Psychology
(2)
Leaves
(2)
Medical Sciences
(2)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Osteoporotic pubic rami fracture: a benign injury?

Use of silver coating in tumoral prosthetic surgery: influence on infection rate

Optimizing chair time in infusion centers using intravenous cetirizine premedication for the prevention of hypersensitivity infusion reactions

Carpal tunnel syndrome due to heterotopic ossification

Final results from TACTI-002 Part C: A phase II study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients with metastatic 2nd line head and neck squamous cell carcinoma unselected for PD-L1

Is physician-patient language discordance a barrier for clinical trial enrollment in patients with cancer? A real-life study

AIPAC-003: A randomized, double-blind, placebo-controlled phase 3 trial testing eftilagimod alpha (soluble LAG-3) in patients with HER2-neg/low metastatic breast cancer receiving paclitaxel, following an open-label dose optimization

RNA sequencing as a confirmatory assay and its impact on patient care in multiple cancer types

TACTI-003: A randomized phase IIb study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab as first-line treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma

Safety and clinical activity of target-preserving anti-CTLA-4 antibody ONC-392 as monotherapy in NSCLC patients who progressed on PD(L)1-targeted immunotherapy

Results from a phase II study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients with PD-L1 unselected metastatic non-small cell lung carcinoma

A phase II study (TACTI-002) in first-line metastatic non–small cell lung carcinoma investigating eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab: Updated results from a PD-L1 unselected population

MT-6402, an engineered toxin body (ETB) targeting PD-L1: Interim efficacy and safety data

Initial results from a phase II study (TACTI-002) in metastatic non-small cell lung or head and neck carcinoma patients receiving eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab

Resultado tras el tratamientoquirúrgico de tumores de células gigantes

Ph I/II study of oral selective AXL inhibitor bemcentinib (BGB324) in combination with erlotinib in patients with advanced EGFRm NSCLC: End of trial update

Operational metrics for the ELAINE II study combining a traditional approach with a just-in-time model

A multicenter, phase II study of soluble LAG-3 (Eftilagimod alpha) in combination with pembrolizumab (TACTI-002) in patients with advanced non-small cell lung cancer (NSCLC) or head and neck squamous cell carcinoma (HNSCC)

A phase II, open-label study of tomivosertib (eFT508) added on to continued checkpoint inhibitor therapy in patients (pts) with insufficient response to single-agent treatment

Leveraging machine learning technology to efficiently identify and match patients for precision oncology clinical trials

A phase 1b, open-label, single-arm study of cofetuzumab pelidotin (a PTK7-targeting antibody-drug conjugate) in patients with PTK7-expressing, recurrent non-small cell lung cancer (NSCLC)

Safety and efficacy of eflapegrastim in reducing severe neutropenia in patients treated with myelosuppressive chemotherapy in a phase 3 randomized controlled trial compared to pegfilgrastim (ADVANCE trial)

Uso de recubrimientos protésicos de plata en cirugía tumoral: influencia en la tasa de infección

Genomic mutation profiling (GMP) and clinical outcome in patients (pts) treated with ribociclib (CDK4/6 inhibitor) in the Signature program

Operational Metrics for the ELAINE 2 Study Combining a Traditional Approach With a Just-in-TIME Model

Suchergebnisse filtern